Introduction
The treatment of myeloma has been transformed in recent years by a combination of novel therapies such as thalidomide and the increasingly widespread use of highdose procedures such as autologous and, to a lesser extent, allogeneic stem cell transplants. The latter trend is illustrated by an EBMT study showing that just a few hundred haematopoietic stem cell transplants were performed per year for myeloma in Europe in 1990 whereas in 2002 there were over 4000. 1 Average life expectancy for patients with myeloma is typically around 3-5 years and most patients will die from the disease despite many changes to treatment during the last 20 years. High-dose chemotherapy with peripheral blood stem cell support has been shown to prolong life expectancy compared to standard chemotherapy in some 2, 3 but not all studies. 4 A recent study has also suggested that a tandem transplant protocol may be superior to a single transplant for certain patients. 5 Allogeneic transplant may cure around 20-30%
of patients with myeloma 6 but only a small number of people are young and fit enough to undergo such a procedure. In order to succeed, such high-dose therapy strategies must be accompanied by effective use of supportive measures to prevent and treat common complications of therapy. To this end, colony stimulating factors (CSFs) and erythropoietin (Epo) have been enjoying increasing popularity in a number of different contexts and their use to support high-dose procedures will be reviewed here.
Colony stimulating factors
Granulocyte colony stimulating factor (G-CSF) was identified as a substance which specifically induced the formation of neutrophil colonies when added to human or mouse bone marrow cells in culture. 7 Granulocyte-macrophage stimulating factor (GM-CSF), as its name suggests, was found to increase the production of eosinophils, macrophages and dendritic cells in addition to granulocytes. G-CSF is a glycoprotein of molecular weight 19 kDa and is produced by a number of cell types including endothelial cells. In the mid 1980s, the gene encoding G-CSF was cloned and located on chromosome 17q which opened the door to the production of recombinant human G-CSF (rhG-CSF). Subsequent structural analyses of the protein itself have shown the existence of four antiparallel alpha-helices which cluster together to form a helical bundle with the resulting tertiary structure conferring specificity of binding to the G-CSF receptor. 8 The action and specificity of G-CSF is mediated through its specific transmembrane receptor which is expressed on cells from the myeloblast to the mature neutrophil with the highest number of receptors on the mature neutrophil.
9 G-CSF has been implicated in a number of physiological processes, including the basal production of granulocytes by the bone marrow and the emergency response of the bone marrow to increase production of granulocytes in the setting of acute infection. Indeed, mice which have low endogenous G-CSF display a marked neutropenia in combination with a failure to mobilize granulocytes during infections. 10 These effects are thought to be primarily due to maturation and proliferation signals being delivered to myeloid precursors in the bone marrow. In addition to its effects on the bone marrow granulocyte precursors, G-CSF also has effects on peripheral mature neutrophils. These include effects on degranulation, 11 adhesion, 12 phagocytosis 13 and delaying apoptosis.
14 Of crucial importance in the setting of stem cell transplantation, G-CSF has also been implicated in the mobilization of immature haematopoietic precursors from the bone marrow into the peripheral circulation although this topic will not be dealt with further in this review.
Efficacy of CSFs as infection prophylaxis during high-dose procedures
A number of randomized, controlled clinical trials have been performed on the use of rhG-CSF in primary prophylaxis during high-dose procedures for a number of haematological cancers and solid tumours, and a recent large meta-analysis has been performed. 15 The majority of the studies show a reduction in documented infections, in days of parenteral antibiotic use and in time to discharge. However, no statistically significant reduction in either overall mortality or infection-related mortality has been demonstrated. For example, one of the more recent, larger studies which was randomized and double-blinded compared lenograstim at a dose of 150 mg/m 2 per day from day þ 1 after autologous PBSC infusion with placebo. Lenograstim treatment was associated with a reduction in the number of patients experiencing at least one infectious episode from 86/94 patients to 66/98 patients. 16 A significant reduction in the average number of days of intravenous antibiotics was observed (from 10 days to 8 days) along with a significant reduction in the time to neutrophil recovery (defined as achieving an absolute neutrophil count of 40.5 Â 10 9 /l) from 15 to 11 days. Mean hospital stay was reduced from 17 to 15 days. The observed improvement in a number of clinical parameters has led some investigators to conclude that there may be an economic benefit of using rhG-CSF as primary prophylaxis. One of the early reports by Luce et al. 17 concluded that the initial average cost of an autologous bone marrow transplant for lymphoid cancer fell by 21% in patients treated with rhGM-CSF largely due to a reduction in the length of hospital stay. Subsequent analyses of the costeffectiveness of rhCSFs (both GM-CSF and G-CSF) in this setting sometimes agreed with this early report 18, 19 whereas others have drawn an opposite conclusion. 20, 21 It might be argued that since the introduction of better tolerated but significantly more expensive antifungal therapy, the cost benefit for rhG-CSF is likely to become more pronounced with time. However, one of the more recent cost analyses concluded that there was a cost saving associated with the placebo group. 22 It is therefore currently premature to conclude that primary prophylaxis of CSFs is associated with a significant financial saving. 15 The cost of G-CSF may be reduced by optimization of the dosing schedule. To this end, several studies have compared the efficacy of G-CSF when started later than day þ 1 after stem cell infusion. Unfortunately, results are conflicting with studies by Bence-Bruckler et al. 23 (comparing day þ 1 with day þ 7) and Bolwell et al. 24 (comparing day 0 with day þ 3 with day þ 5) showing no difference in efficacy whereas a study by Colby et al. 25 (comparing day þ 1 with day þ 4) showing a significant benefit for early therapy, although this study was retrospective. Not surprisingly, delayed therapy was associated with a significant cost saving and this finding really should be subjected to a more rigorous, large randomized study. In summary, the clear efficacy of rhG-CSF with respect to a number of different parameters has led the American Society of Oncology (ASCO) to consider primary prophylaxis with this agent during highdose therapy with autologous stem cell support as the standard of care. 26 CSFs as treatment for therapy-induced febrile neutropenia An alternative to use of G-CSF therapy as primary prophylaxis is to administer these agents alongside antibiotics to patients who have developed a febrile illness whilst neutropenic. There are fewer studies assessing this approach and the data are mainly in the setting of solid tumour patients receiving chemotherapy. Results from some of the rather small trials addressing the use of G-CSF or GM-CSF in this situation were also conflicting with some suggesting an improvement in time to recovery of fever 27, 28 while others failed to show a benefit. 29 Clark et al. 30 undertook a meta-analysis of randomized-controlled trials in an effort to provide clarity. A clear and expected reduction in duration of neutropenia was observed as was the duration of hospitalization. Although no effect on overall survival was demonstrated, a marginally significant reduction in infection-related mortality was observed. Interestingly, it appeared on sub-group analysis that the groups most likely to benefit from this approach were those patients with haematological malignancies. The results of this and one other 31 meta-analysis have prompted ASCO to recommend adjunctive G-CSF therapy for patients with febrile neutropenia and a clinical risk factor for the development of complications, such as expected prolonged and profound neutropenia, old age, pneumonia, hypotension and multi-organ dysfunction. 26 
CSFs and graft-versus-host disease
One serious concern that has arisen with the use of CSFs in the allogeneic stem cell transplant setting is the possibility of a higher rate of graft-versus-host disease which is one of the major causes of morbidity and mortality following such a procedure. Indeed, the ASCO guidelines specifically state that CSF use after autologous, but not allogeneic, transplantation is the current standard of care. 26 This recommendation is largely based on the conclusions of a European study which looked at the outcome of 1789 patients with acute leukaemia receiving bone marrow transplantation and 434 patients receiving PBSC transplantation. 32 In the bone marrow transplantation group, G-CSF therapy within the first 14 days after marrow infusion was associated with a statistically significant increase in incidence of grades II-IV acute GvHD (from 39 to 50%), in incidence of chronic GvHD (relative risk 1.29) and in transplant-related mortality (relative risk 1.79).
There was no effect on the leukaemia relapse rate but there was a reduction in overall survival and leukaemia-free survival. Interestingly, no such effect was seen in the PBSC group although the numbers were smaller. The observed increase in the acute GvHD incidence has also been shown by other groups. 33, 34 However, the studies which demonstrate these results are all retrospective analyses which are susceptible to bias. Indeed, the recent meta-analysis by Dekker et al. 15 which included only prospective, randomized-controlled trials did not find any significant association between CSF use and acute or chronic GvHD, treatment-related mortality or overall survival. The study inclusion criteria means that the result obtained should be free of the potential confounding factors which are so difficult to control for in retrospective analyses. Publication bias is an issue for meta-analyses but this tends to produce a falsely positive result whereas in this case the result was negative. Another earlier meta-analysis by Ho et al. 35 came to a similar conclusion although data were included from prospective and retrospective studies. In short, results from some retrospective and prospective trials are conflicting. Although the results from prospective trials are more robust, the total number of patients included in these studies is much lower than that in the single retrospective study by Ringden et al. 32 In fact, the largest study of allogeneic patients included in the meta-analysis by Dekker et al. contained just over 100 patients. 36 To clarify the issue therefore, a large multicentre, prospective, randomized trial is required.
Which CSF to use
An obvious question for the use of CSF support during high-dose procedures is which agent to use. Early in vitro studies suggested that the glycosylated form of G-CSF (lenograstim) had more biological activity than filgrastim. 37, 38 Studies have also been reported which tested the potency of CSF in healthy volunteers to mobilize CD34 þ progenitor cells and they too suggested that lenograstim was more potent than filgrastim. 39, 40 However, no difference between the drugs has been identified in clinical studies. Certainly when CSFs are used to mobilize stem cells prior to autologous stem cell transplantation, the weight of evidence suggests there is no significant difference in the potency of filgrastim, lenograstim and the GM-CSF preparation molgramostim. 41, 42 Fewer studies have compared these agents as primary prophylaxis during autologous or allogeneic stem cell transplantation. Bonig et al. 43 performed the first prospective randomized comparison of filgrastim with lenograstim as primary prophylaxis during chemotherapy in paediatric patients. This trial has only small numbers in each group (only 11) and showed no difference in a number of different laboratory and clinical outcomes. A retrospective comparison of patients undergoing PBSC transplantation following high-dose therapy actually showed a more rapid neutrophil recovery and platelet recovery along with a reduced duration of antibiotic therapy and a shorter hospital stay with filgrastim. 44 A more recent retrospective analysis however showed no difference between the two agents. 45 At present, there is insufficient evidence to recommend one form of rhG-CSF over another. A more recent compound to have come onto the market is a pegylated form of filgrastim called pegfilgrastim which maintains biological activity yet has a substantially longer half-life compared with filgrastim due to decreased renal excretion. 46, 47 A phase II trial studied 38 patients with myeloma or lymphoma undergoing high-dose therapy with autologous stem cell support who were all given a single subcutaneous (sc) injection of 6 mg pegfilgrastim on day þ 1 following stem cell infusion. 48 Neutrophil engraftment was compared with historical controls and shown to be similar to that achieved with filgrastim yet significantly shorter than in patients who did not receive CSF support. A subsequent prospective, randomized study comparing pegfilgrastim administered on day þ 1 after the stem cell infusion with filgrastim administered daily commencing on day þ 5, in myeloma patients receiving high-dose melphalan and autologous stem cell transplants showed no statistical difference between time to neutrophil engraftment and platelet engraftment. 49 However, in the pegfilgrastim group there was a significantly greater white cell count on day þ 15 (6.0 Â 10 9 /l compared with 2.7 Â 10 9 /l) together with a reduction in the incidence of febrile neutropenia from 100 to 61% and a reduction in the duration of febrile neutropenia from 4 days to 1.5 days. The total number of patients randomized were only 37, so a larger study is clearly needed in order to confirm this intriguing result. At present, it is too early to clearly define a role for pegfilgrastim in high-dose therapy protocols.
GM-CSF is rarely used in high-dose therapy procedures. A randomized study comparing the CD34 þ cell mobilizing efficacy of filgrastim, lenograstim and molgramostim (GM-CSF) showed no statistically significant differences between the three compounds. 42 However, only one study has assessed its use during subsequent high-dose therapy. Legros et al. 50 performed a randomized, placebo-controlled trial and showed that the use of GM-CSF had no effect on the time to neutrophil engraftment or on the incidence of documented infections. In fact, the placebo group actually had significantly fewer days of fever. There was a suggestion that GM-CSF may result in more rapid platelet engraftment and reduced severity of mucositis 51, 52 but this was not born out in subsequent clinical trials. 42, 50 The demonstrated lack of benefit over placebo means that current formulations of GM-CSF are unlikely to be used widely in high-dose therapy programmes.
Long-term safety of CSFs
There has been intense scrutiny over the safety of G-CSF therapy in large part due to its frequent use in healthy stem cell donors as part of an allogeneic transplant. A report which generated concern was recently published by the Research on Adverse Drug Events and Reports project which identified 2 out of 200 healthy donors who went on to develop acute myeloid leukaemia some years after having received G-CSF as part of stem cell mobilization for a sibling allogeneic transplant regimen. 53 It is impossible to demonstrate a causative role for the G-CSF in these cases, particularly in view of the described increased risk of acute leukaemia in first degree relatives. 54 More reassuringly, the National Marrow Donor Programme in America has not reported any cases of leukaemia in more than 4000 volunteer, unrelated stem cell donors to date. 55 Of more concern to patients receiving G-CSF as part of a stem cell transplant regimen are recent reports of case-control studies linking use of G-CSF with an increased risk of developing subsequent myelodysplastic syndrome/ AML. 56, 57 The relative risk ranged from 2 to 4 although the absolute risk remained low. These studies do highlight the fact that such patients merit prolonged follow up.
Introduction to erythropoietin
Erythropoietin (Epo) is a heavily glycosylated glycoprotein hormone encoded by a gene which is located on chromosome 7q11-22. 58 The resulting 165 amino acid glycoprotein acts to promote erythroid proliferation, differentiation and survival with a resulting increase in the mass of circulating red cells. 59 The major site of Epo production is the renal peritubular cell although in adult life 10% is produced by the liver. The liver plays a more important role in Epo synthesis during fetal life, the switch to predominant renal production occurring at about 30 weeks of gestation. 60 RHuEpo is synthesized by Chinese Hamster Ovary cells and has the identical 165 amino acid sequence to endogenous circulating human Epo. 61 The molecule contains two disulphide bonds between residues 7 and 161 and 29 and 33, and the disruption of these bonds results in instability of the molecule along with reduced biological activity. A total of 60% of the mass of RHuEpo is protein whereas 40% is carbohydrate, and the glycosylation status of the Epo molecule is also important for determining certain biological properties. The three N-linked sugars (at positions 24, 38 and 83) are necessary for persistence of the molecule within the circulation. Removal of these sugars produces a biologically active Epo molecule but with a much reduced circulating half-life. 62 There is in addition one O-linked sugar (at position 126) which does not appear to be of functional importance.
Two Epos, epoetin-a and epoetin-b are currently available plus darbepoetin, a longer acting derivative. A number of erythropoietic agents are in development including epoetin delta and CERA (continuous erythropoietin receptor activator). As with other glycoprotein hormones, Epo exists as a mixture of different isoforms which differ mainly in their glycosylation pattern. 63 Epo binds to the dimeric erythropoietin receptor (EpoR) which is a member of the cytokine receptor superfamily. Receptor binding induces a conformational change which has the effect of bringing the cytoplasmic tails of the two subunits into closer proximity. 64 This enables the EpoR-associated tyrosine kinase Jak2 (a member of the Janus kinase family) to phosphorylate tyrosine residues which reside in the cytoplasmic domain of the partner subunit. Once phosphorylated, signal transducer and activator of transcription 5 (STAT5) can interact with the EpoR via Src-homology 2 domains, resulting in subsequent translocation to the nucleus and modulation of gene expression. 65 A number of genes are modulated by STAT5 but one of particular importance is Bcl-x. The level of this molecule in erythroid progenitors is increased by the action of Epo and it is thought to protect cells from undergoing apoptosis. 66 Along with bone pain, renal impairment and an increased incidence of infection, anaemia is a common complication of myeloma. More specifically, anaemia is present in approximately 50% of patients at the time of diagnosis and most of the remainder will develop anaemia at some point during the course of their illness. 67 The anaemia may have many causes but the most common explanations include the cytokine driven anaemia of chronic disease (AOCD) plus the myelotoxic impact of treatment with chemo and/or radiotherapy. 68 Cytokines such as tumour necrosis factor-a, g-interferon and interleukin-1 contribute to the AOCD by shortening red cell survival, blunting erythropoiesis both directly and indirectly (by reducing Epo production) and by inhibiting the availability of tissue iron. 68 Hepcidin, a peptide produced in the liver, increases in patients with AOCD and has been shown to be a key player in reducing iron absorption by gut enterocytes and blocking iron release from tissue macrophages. 69 Recently, it was suggested that malignant plasma cells expressing Fas ligand and TRAIL (TNF-related apoptosis inducing ligand) was a major pathogenetic mechanism for anaemia in patients with myeloma. 70 Anaemic patients with myeloma may benefit from treatment with recombinant Epo which can improve the haemoglobin concentration, decrease transfusion need and improve quality of life. 71 Because of the success of recombinant Epo in treating anaemia in myeloma patients undergoing standard chemotherapy, 72, 73 a number of studies were designed to determine its effectiveness in patients receiving high-dose therapy with stem cell support.
Erythropoietin after high-dose chemotherapy with autologous marrow or peripheral blood stem cell support
The majority of patients are anaemic on admission to hospital for high-dose treatment as a consequence of their underlying disease and its treatment. A recent survey of the Oxford myeloma patients admitted for high-dose treatment showed that 76% were anaemic with a haemoglobin of o12.0 g dl
À1
. Several relatively small trials of Epo treatment after high-dose chemotherapy and autologous transplant have been performed. Until recently, all these studies reported no benefit in terms of haemoglobin concentrations and a reduction in transfusion need from Epo. Perhaps the best of these trials was the randomized, placebo-controlled trial reported by Link et al. 74 One-hundred and fourteen patients with haematological malignancies were randomized to rHuEpo or placebo by continuous IV infusion after high-dose chemotherapy and autologous transplant. Treatment was continued until transfusion independence or until day þ 41. There was no advantage for the patients treated with rHuEpo in terms of haemoglobin concentrations and time to transfusion independence.
More encouraging results have been reported since then by a number of groups who have investigated treatment with rHuEpo at different time points both before and after high-dose chemotherapy. Martino et al. 75 treated 22 patients with myeloma with rHuEpo by daily sc injection starting 30 days before high-dose treatment. A total of 40 similar patients who did not receive rHuEpo were selected as historical controls. Although there was no significant difference between the haemoglobin concentrations of the two groups at the time of transplant, the treatment group had a significantly better nadir haemoglobin (median 10.0 versus 7.6 g/dl) and fewer than 20% of the treatment group required blood transfusions compared to more than half of the control patients.
Baron et al. 76 have shown that after high-dose chemotherapy serum Epo concentrations are higher than expected for the degree of anaemia for 1-3 weeks. During this time the marrow erythroid activity is suppressed from the chemotherapy and therefore it is not surprising that treatment with rHuEpo during the first 3-4 weeks after high-dose treatment is not effective. They hypothesized that starting rHuEpo 4 weeks after high-dose treatment, at a time when serum Epo levels were normal or sub-optimal for the degree of anaemia, but erythroid activity was recovering, would be advantageous. They treated 41 patients (rHuEpo 500 U/kg per week by sc injection) with myeloma or lymphoma and compared them to an historical control group. In the treatment group, 87% achieved the target haemoglobin of 13.0 g/dl within 12 weeks of starting rHuEpo compared with 14% in the controls. No patient in the treatment group required transfusion after rHuEpo was started compared to 8/45 patients in the control group. Encouraged by these results, the same group has reported a small randomized trial of rHuEpo starting on day þ 30 versus no treatment in 20 patients (of whom 13 had myeloma) undergoing high-dose chemotherapy with peripheral blood stem cell support. 77 At day 30, the mean serum Epo concentration was sub-optimal for the degree of anaemia in the treatment and control groups of patients. All the patients in the treatment group responded with a greater than 2.0 g/dl rise in Hb versus a 28% response in the control group.
A total of 90% of patients in the rHuEpo group achieved a haemoglobin 412.0 by day 100, whereas only 40% of patients achieved this target in the control group. This small randomized study provides some more interesting data supporting the investigators' hypothesis that delaying rHuEpo after high-dose chemotherapy until red cell production is recovering, and endogenous Epo concentrations are sub-optimal results in speedier red cell recovery than in a control group. However, in this study, there was no difference in transfusion need between the treatment and control groups.
Erythropoietin after allogeneic bone marrow or peripheral blood stem cell transplant Link et al. 74 conducted a study in which 215 patients scheduled for allogeneic bone marrow transplant using myeloablative conditioning were randomized to rHuEpo (150 IU kg À1 per day by continuous intravenous infusion from day 0 to transfusion independence or a maximum of 41 days) or placebo. The median time to red cell independence was 19 days in the treatment group versus 27 days in the placebo group. There was no impact on the number of red cell units transfused between the two groups between day 0 and 20 but after this time the treatment group required fewer transfusions. Other investigators have also reported benefit for treatment with rHuEpo after allogeneic transplant. 78, 79 Exploiting the same argument as in the autologous setting, Baron et al. 80 showed that treatment with rHuEpo starting at day þ 30 or beyond, in patients transplanted with allogeneic peripheral blood stem cells, resulted in transfusion independence within 2 weeks in 12/13 patients versus 50% of patients in an historical control group. The mean Hb concentrations were significantly higher in the treatment compared to the control groups from day þ 60 post-transplant. In this study, the investigators also showed that serum Epo concentrations were normal or high until day þ 28 and then became inappropriately low for at least the next 6 months. The persistently lower Epo concentrations in allograft compared to autograft patients may be in part attributable to renal damage induced by immunosuppressive agents such as cyclosporine.
Safety
In the studies described above Epo was safe with no increased risk of hypertension or venous thrombosis. During the last few years, two major concerns have been raised about erythropoetic agents. Firstly, in patients with renal failure Casadevall et al. 81 described the development of pure red cell aplasia caused by the development of antiEpo antibodies. This rare complication seemed to be confined to patients with renal failure treated with one of the agents (epoetin-a). Changes in manufacturing practice were undertaken and the complication has largely disappeared.
Secondly, there remains doubt about the possible adverse impact of the erythropoetic agents on survival in patients with cancerous illnesses. A number of studies in head and neck cancer, breast cancer and non-small cell lung cancer have suggested a survival disadvantage for patients treated with Epo compared to placebo. 82 The subject remains widely debated as many other studies show either a survival advantage or no disadvantage between treatment and control groups. 83 The trials in myeloma described above have not shown any concerns about the survival of the Epo compared to the control treatment arms.
Conclusions
Due to the large number of studies performed and more than one published meta-analysis, it is clear that G-CSF use as primary prophylaxis during autologous PBSC transplantation in myeloma and other tumours confers several benefits such as reduced antibiotic usage and time to discharge and this is reflected in the recommendations issued by both ASCO and the British Committee for Standards in Haematology. 26, 84 It should be emphasized however that a survival advantage has not been shown and so some centres do not routinely administer such agents. The evidence for a worse outcome for patients undergoing allogeneic bone marrow transplantation treated with G-CSF is, in the opinion of the authors, far from conclusive and further studies are urgently needed to address this issue. Pegfilgrastim is an interesting new agent and may well come to be used increasingly as primary infection prophylaxis during high-dose procedures although larger studies are required to establish its role. Certainly patients are likely to prefer its single dose to the sometimes arduous daily dosing regimes of the conventional G-CSF formulations.
The problem in interpreting all of the Epo studies is that there are too few patients included. If, however, they are taken at face value, the suggestion is that using recombinant Epo before and/or starting around 30 days after highdose chemotherapy with stem cell support will significantly increase the haemoglobin concentration and decrease transfusion need. There are no data on quality of life and no information about whether anaemia correction could have any impact on life expectancy or the duration of response. Is any of this important when you remember that high-dose treatment is just one aspect in the total care package for people with myeloma? Well, in 2005, nearly 6000 people in Europe with myeloma underwent high-dose treatment with autologous stem cell support. 85 If treatment with Epo decreases transfusion requirements by just one unit per patient then this would be an important reduction in the total amount of red cell units across the continent. The real reduction may be greater than this. Whether such a reduction in use would be deemed costeffective will depend on the health economy of each individual country; but if the availability of red cells for transfusion declines further any strategy to reduce use will be welcomed. The reported studies seem to indicate that the timing of Epo use is probably of great importance in obtaining the maximum benefit; but much larger trials are needed before recombinant Epo can be unequivocally recommended in this field.
